Literature DB >> 9334726

Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading.

S D Miller1, C L Vanderlugt, W S Begolka, W Pao, R L Yauch, K L Neville, Y Katz-Levy, A Carrizosa, B S Kim.   

Abstract

Multiple sclerosis (MS) is a T cell-mediated autoimmune demyelinating disease, which may be initiated by a virus infection. Theiler's murine encephalomyelitis virus (TMEV), a natural mouse pathogen, is a picornavirus that induces a chronic, CD4+ T cell-mediated demyelinating disease with a clinical course and histopathology similar to that of chronic progressive MS (ref. 3). Demyelination in TMEV-infected mice is initiated by a mononuclear inflammatory response mediated by virus-specific CD4+ T cells targeting virus, which chronically persists in the CNS (ref. 4-6). We show that beginning 3-4 weeks after disease onset, T-cell responses to multiple myelin autoepitopes arise in an ordered progression and may play a pathologic role in chronic disease. Kinetic and functional studies show that T-cell responses to the immunodominant myelin proteolipid protein epitope (PLP139-151) did not arise because of cross-reactivity between TMEV and self epitopes (that is, molecular mimicry), but because of de novo priming of self-reactive T cells to sequestered autoantigens released secondary to virus-specific T cell-mediated demyelination (that is, epitope spreading). Epitope spreading is an important alternate mechanism to explain the etiology of virus-induced organ-specific autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9334726     DOI: 10.1038/nm1097-1133

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  187 in total

1.  Lack of restriction of T cell receptor beta variable gene usage in cerebrospinal fluid lymphocytes in acute optic neuritis.

Authors:  R N Heard; S M Teutsch; B H Bennetts; S D Lee; E M Deane; G J Stewart
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-11       Impact factor: 10.154

Review 2.  New concepts of the etiopathogenesis and treatment of insulin-dependent diabetes mellitus.

Authors:  J F Bach
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

3.  The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis.

Authors:  D A Hafler
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

4.  T cell-independent rescue of B lymphocytes from peripheral immune tolerance.

Authors:  V Kouskoff; G Lacaud; D Nemazee
Journal:  Science       Date:  2000-03-31       Impact factor: 47.728

Review 5.  Mechanisms for the induction of autoimmunity by infectious agents.

Authors:  K W Wucherpfennig
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 6.  The origin and regulation of autopathogenic T cells.

Authors:  A C Anderson; L B Nicholson; V K Kuchroo
Journal:  J Clin Immunol       Date:  2001-03       Impact factor: 8.317

7.  CD28 costimulatory blockade exacerbates disease severity and accelerates epitope spreading in a virus-induced autoimmune disease.

Authors:  K L Neville; M C Dal Canto; J A Bluestone; S D Miller
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

8.  Theiler's virus infection of primary cultures of bone marrow-derived monocytes/macrophages.

Authors:  Cécile Martinat; Ignacio Mena; Michel Brahic
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

9.  Role of pathogenic T cells and autoantibodies in relapse and progression of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in LEW.1AV1 rats.

Authors:  Yoh Matsumoto; Il-Kwon Park; Keiko Hiraki; Shin Ohtani; Kuniko Kohyama
Journal:  Immunology       Date:  2008-10-29       Impact factor: 7.397

Review 10.  Neuroimmune interactions in a model of multiple sclerosis.

Authors:  C Jane Welsh; Andrew J Steelman; Wentao Mi; Colin R Young; Ralph Storts; Thomas H Welsh; Mary W Meagher
Journal:  Ann N Y Acad Sci       Date:  2009-02       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.